These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 15820096

  • 1. A one-year clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy.
    Zhou HY, Zheng YH, Zhang CY, Ding PP, Zou W.
    Chin Med J (Engl); 2005 Apr 05; 118(7):609-11. PubMed ID: 15820096
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years.
    Zhou HY, Zheng YH, Zhang CY, Chen J, He Y, Ding PP, Li H.
    Viral Immunol; 2007 Apr 05; 20(1):180-7. PubMed ID: 17425432
    [Abstract] [Full Text] [Related]

  • 3. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 4. Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin.
    Olawumi HO, Olatunji PO, Salami AK, Odeigah L, Iseniyi JO.
    Niger J Clin Pract; 2008 Dec 13; 11(4):312-5. PubMed ID: 19320401
    [Abstract] [Full Text] [Related]

  • 5. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F, VIRGO Study Team.
    Antivir Ther; 1999 Dec 13; 4 Suppl 3():83-4. PubMed ID: 16021876
    [Abstract] [Full Text] [Related]

  • 6. [A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].
    Zheng YH, Yang X, Chang WH.
    Hunan Yi Ke Da Xue Xue Bao; 2003 Aug 13; 28(4):390. PubMed ID: 14653126
    [No Abstract] [Full Text] [Related]

  • 7. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Aug 13; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 8. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F.
    HIV Med; 2006 Oct 13; 7(7):431-6. PubMed ID: 16925728
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combining d4T/ddI looks promising.
    Posit Aware; 1996 Oct 13; 7(1):7. PubMed ID: 11363129
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y, Qiu ZF, Li TS, Han Y, Zuo LY, Xie J, Ma XJ, Liu ZY, Wang AX.
    Chin Med J (Engl); 2006 Oct 20; 119(20):1677-82. PubMed ID: 17097013
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B, Staccato Thailand Study Group.
    Antivir Ther; 2008 Oct 20; 13(3):375-80. PubMed ID: 18572750
    [Abstract] [Full Text] [Related]

  • 13. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
    Zala C, Salomón H, Cahn P.
    Antivir Ther; 1999 Oct 20; 4 Suppl 3():95-9. PubMed ID: 16021880
    [Abstract] [Full Text] [Related]

  • 14. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P.
    Southeast Asian J Trop Med Public Health; 2005 Mar 20; 36(2):362-9. PubMed ID: 15916042
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
    Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P.
    J Med Assoc Thai; 2006 Sep 20; 89(9):1472-8. PubMed ID: 17100387
    [Abstract] [Full Text] [Related]

  • 16. Rationale for early antiretroviral therapy in patients with CD4 cell counts > 500 cells/mm3.
    Soriano V, Gómez-Cano M, Mas A, Villalba N, Bravo R, González-Lahoz J.
    Antivir Ther; 1996 Dec 20; 1(4):264-5. PubMed ID: 11324829
    [No Abstract] [Full Text] [Related]

  • 17. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr 20; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 18. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.
    Persaud D, Palumbo P, Ziemniak C, Chen J, Ray SC, Hughes M, Havens P, Purswani M, Gaur AH, Chadwick EG, Pediatric AIDS Clinical Trials Group P1030 Team.
    J Infect Dis; 2007 May 15; 195(10):1402-10. PubMed ID: 17436219
    [Abstract] [Full Text] [Related]

  • 19. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C.
    Clin Infect Dis; 2007 Jan 15; 44(2):295-300. PubMed ID: 17173234
    [Abstract] [Full Text] [Related]

  • 20. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response.
    Kovacs A, Montepiedra G, Carey V, Pahwa S, Weinberg A, Frenkel L, Capparelli E, Mofenson L, Smith E, McIntosh K, Burchett SK, Pediatric AIDS Clinical Trials Group 366 Study Team.
    J Infect Dis; 2005 Jul 15; 192(2):296-302. PubMed ID: 15962224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.